CD8A and fibrosarcoma: Intravenous administration of ES-Cu-MOF nanoparticles concentrated these agents at tumor sites, effectively inhibiting fibrosarcoma growth and enhancing cytotoxic CD8+ T cell infiltration, thereby improving immune responses against the tumor.